Article (Scientific journals)
Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment
Reginster, Jean-Yves; Veronese, N.
2021In Aging Clinical and Experimental Research, 33, p. 37-47
Peer Reviewed verified by ORBi
 

Files


Full Text
Highly purified chondroitin sulfate. a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment..pdf
Publisher postprint (1.16 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Chondroitin sulfate; Economic analysis; Hand osteoarthritis; Hip osteoarthritis; Knee osteoarthritis; Osteoarthritis
Abstract :
[en] Osteoarthritis (OA) is the most prevalent musculoskeletal disease and a major cause of negative relevant outcomes, associated with an ever-increasing societal burden. Pharmaceutical-grade chondroitin sulfate (CS) was repeatedly reported to reduce pain and improve function in patients with OA. This article aims to review the evidence for the role of highly purified (hp) CS (Condrosulf®, IBSA) in the treatment of OA. We collected and reported evidence concerning (1) efficacy of hpCS 800 mg/day in the treatment of OA affecting the knee, hand and hip; (2) efficacy and safety of hpCS 1200 mg/day also in the oral gel formulation; (3) the safety profile of hpCS; (4) the difference of hpCS and pharmaceutical-grade formulations versus food supplements; (5) pharmacoeconomic added value of hpCS. The data support that hpCS is an effective and safe treatment of OA, with its effect already evident at 30 days; in addition, its beneficial action is prolonged, being maintained for at least 3 months after the drug is discontinued. Full safety reports’ analyses confirm that CS is safe to use and has almost no side effects, in particular, it showed better gastrointestinal tolerance if compared with non-steroidal anti-inflammatory drugs (NSAIDs). Moreover, the therapeutic strategy has proved to be cost-effective: treatment with CS reduced the use of NSAIDs and their side effects. © 2020, The Author(s).
Disciplines :
General & internal medicine
Author, co-author :
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Veronese, N.;  Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, 90100, Italy
Language :
English
Title :
Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment
Publication date :
2021
Journal title :
Aging Clinical and Experimental Research
ISSN :
1594-0667
eISSN :
1720-8319
Publisher :
Springer
Volume :
33
Pages :
37-47
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 21 October 2020

Statistics


Number of views
68 (5 by ULiège)
Number of downloads
42 (3 by ULiège)

Scopus citations®
 
28
Scopus citations®
without self-citations
23
OpenCitations
 
19

Bibliography


Similar publications



Contact ORBi